Amarin reported $0 in Loan Capital for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
DBV Technologies DBVT:US 0 0
Aerie Pharmaceuticals AERI:US $ 312.13M 0.45M
Alnylam Pharmaceuticals ALNY:US $ 677.72M 1.01M
Amarin AMRN:US $ 0M 0M
AstraZeneca AZN:LN 27146M 1659M
Epizyme EPZM:US $ 232.9M 411K
Esperion Therapeutics ESPR:US $ 259.08M 402K
GlaxoSmithKline GSK:LN 18784M 10442M
Halozyme Therapeutics HALO:US $ 1147.13M 359.03M
Intercept Pharmaceuticals ICPT:US $ 713.86M 3.03M
IONIS PHARMACEUT IONS:US $ 1248.4M 0.47M
JAZZ PHA JAZZ:US $ 5990M 2.87M
Nektar Therapeutics NKTR:US $ 0M 0M
Neurocrine Biosciences NBIX:US $ 169M 208.7M
Novartis NOVN:VX SF 23784M 589M
Teva Pharmaceutical Industries TEVA:US $ 20363M 477M